A Kaposi’s Sarcoma-Associated Herpesvirus/Human Herpesvirus 8 ORF50 Deletion Mutant Is Defective for Reactivation of Latent Virus and DNA Replication

Yiyang Xu, David P. AuCoin, Alicia Rodriguez Huete, Sylvia A. Cei, Lisa J. Hanson, and Gregory S. Pari*

Department of Microbiology & Immunology, University of Nevada, Reno, Nevada

Received 2 September 2004/Accepted 29 October 2004

Kaposi’s sarcoma-associated herpesvirus (also called human herpesvirus type 8 [HHV8]) latently infects a number of cell types. Reactivation of latent virus can occur by treatment with the phorbol ester tetradecanoyl phorbol acetate (TPA) or with the transfection of plasmids expressing the lytic switch activator protein K-Rta, the gene product of ORF50. K-Rta expression is sufficient for the activation of the entire lytic cycle and the transactivation of viral genes necessary for DNA replication. In addition, recent evidence has suggested that K-Rta may participate directly in the initiation of lytic DNA synthesis. We have now generated a recombinant HHV8 bacterial artificial chromosome (BAC) with a large deletion within the ORF50 locus. This BAC, BAC36Δ50, failed to produce infectious virus upon treatment with TPA and was defective for DNA synthesis. Expression of K-Rta in trans in BAC36Δ50-containing cells was able to abolish both defects. Real-time PCR revealed that K-bZIP, ORF40/41, and K8.1 were not expressed when BAC36Δ50-containing cells were induced with TPA. However, the mRNA levels of ORF57 were over fivefold higher in TPA-treated BAC36Δ50-containing cells than those observed in similarly treated wild-type BAC-containing cells. In addition, immunohistochemical analysis showed that while the latency-associated nuclear antigen (LANA) was expressed in the mutant BAC-containing cells, ORF59 and K8.1 expression was not detected in TPA-induced BAC36Δ50-containing cells. These results showed that K-Rta is essential for lytic viral reactivation and transactivation of viral genes contributing to DNA replication.
the accumulation of mRNA encoding ORF57, a viral transac-
tivator. BAC36Δ50 was efficiently rescued, with respect to pro-
duction of infectious virus and DNA replication, upon the
expression of K-Rta in trans in BAC36Δ50-containing cells. These
data indicated that K-Rta is essential for lytic viral
reactivation and transactivation of viral genes contributing to
DNA replication.

MATERIALS AND METHODS

Cells. 293 cells were maintained in Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum. BAC36-infected 293 cells obtained
from S. Gao (University of Texas) (35) were maintained in Dulbecco's modified
Eagle's medium supplemented with 10% fetal bovine serum and 1 mg of hygro-
mycin per ml. BCBL-1 cells infected with HHV8 were cultured with RPMI 1640
medium supplemented with 20% heat-inactivated fetal bovine serum. To induce
HHV8 lytic replication, the cultured cells were treated with 25 ng of 12-O-
tetradecanoylphorbol-13-acetate (TPA; Sigma) per ml and 1,000 units of alpha
interferon per ml for 2 to 4 days.

Plasmids. BAC DNA containing the HHV8 genome (BAC36) was purified
from BAC36-infected 293 cells with an alkaline lysis procedure (27) and trans-
formed into Escherichia coli strain DH10B by electroporation. The shuttle plas-
mid pST76K_Sr was obtained from M. Messerle, Max con Pettenkofer Institute (3).
ORF50 and its flanking sequence (nucleotides 69405 to 77640) was PCR
amplified with HHV8 genome DNA as the template and the primer set forward, 5'-TGGATACAAAGACGATGACGA-3', and reverse, 5'-CTTTATTTGTGGCCTCGATACTAGGTCACT-3', using Pfu DNA polymerase. The 8.2-kb
PCR product was ligated into the pGEM-T easy Vector (Promega, catalog number A1360) according to the manufacturer's protocol to generate construct
pGEM-ORF50flank. A 7.6-kb fragment containing ORF50 and its flanking se-
quence (nucleotides 69405 to 77603) was released by cleaving pGEM-
ORF50flank with NotI, treated with E. coli DNA polymerase Klcent fragment,
and ligated into pST76K_Sr cleaved with SmaI. The resultant construct, pKSR-
ORF50flank, was then cleaved with ApaI and upon removal of 1.21 kb of DNA
sequence within ORF50, the plasmid was religated to make the construct pKSR-
ORF50mut. This final construct was then used as a shuttle plasmid to generate
an HHV8 BAC recombinant with a deletion within the ORF50 gene locus.

The K-Rta expression plasmid pCMV RTA 5'Flag was a gift from Ren Sun
(University of California–Los Angeles). pOPRSVI-50 which contains ORF50
(K-Rta) with the Flag epitope in the same reading frame context was subcloned
from BAC36-infected 293 cells with an alkaline lysis procedure (27) and trans-
formed into DH10B bacteria that already contained pCMVlacZ (Strategene) and
used to generate the inducible ORF50 cell line.

BAC mutagenesis. Mutagenesis of the HHV8 BAC plasmid was performed
according to the protocol provided by M. Messerle (3). Briefly, shuttle plasmid
pKSR-ORF50mut was electroporated into E. coli DH10B bacteria that already contained
HHV8 BAC36. Transformants were selected at 30°C on Luria-Bertani (LB)
agar plates containing chloramphenicol (15 μg/ml) and kanamycin (50
μg/ml). Clones containing cointegrates were identified by streaking the bacteria
onto LB plates containing chloramphenicol (15 μg/ml) and kanamycin (50
μg/ml) followed by incubation at 43°C. To allow resolution of the cointegrate
cloned plasmids were streaked onto LB plates containing chloramphenicol (15 μg/ml) and incubated at 30°C.

To select clones that had resolved the cointegrate and that contained
the mutant BAC plasmid, bacteria were restreaked onto LB plates containing
chloramphenicol (15 μg/ml) and 5% sucrose. Resolution of the cointegrate was
confirmed by testing for the loss of the kanamycin marker encoded by the shuttle
plasmid. BAC plasmid DNA was isolated from 10-ml overnight cultures by the
alkaline lysis procedure and characterized by restriction enzyme analysis fol-
lowed by Southern blot analysis. Large preparations of HHV8 BAC plasmids
were obtained from 500-ml E. coli cultures with the Qiagen Large construct kit
according to the instructions of the manufacturer.

Southern blot analysis. The DNA probe used for Southern blot hybridizations
was amplified as a 1.4-kb fragment (corresponding to the ORF50 locus) with the
HHV8 genome as the template and primer set forward, 5'-ATGACGGCGGG
tgAGCCTGCTCCTACGACC-3', and reverse, 5'-TTGACGAATACCTGACAA
CAGGCGCTG-3'. Purified HHV8 BAC plasmid DNA was cleaved with Hind
III and separated by electrophoresis on 0.5% agarose gels in 1X Tris-borate-
EDTA buffer for 14 to 18 h at 2.5 V/cm. DNA fragments were visualized by ethidium bromide staining, denatured, and transferred to Zeta-Probe GT
genomic stained blotting membranes (Bio-Rad). DNA probes were radiolabeled
with [α-32P]dCTP (Amersham) with the Rediprime II random prime labeling
system (Amersham). Prehybridization was performed at 65°C for 1 h in hybrid-
ization buffer (5% sodium dodecyl sulfate, 10% polyethylene glycol, 1.5X SSEP
[1X SSEP is 0.18 M NaCl, 10 mM NaPO4, and 1 mM EDTA, pH 7.7]). DNA
blots were hybridized with radiolabeled probes in the same solution at 65°C for
about 16 h. Blots were washed twice for 15 min with 2X SSC (1X SSC is 0.15 M
NaCl plus 0.015 M sodium citrate)-0.1% sodium dodecyl sulfate and twice for
30 min with 0.1X SSC-0.1% sodium dodecyl sulfate at 65°C. Blots were exposed to
X-ray film for 3 to 5 h at room temperature.

Establishment of stable BAC36Δ50-containing 293 cell lines. 293 cells
were transfected with purified BAC36Δ50 DNA with Lipofectamine 2000 (Invitrogen)
according to the manufacturer's instructions. Stable cell lines harboring
BAC36Δ50 were selected with 1 mg of hygromycin per ml.

Generation of an inducible ORF50 (K-Rta) 293 cell line. 293-LAC50, 293 cells
were cotransfected with pOPRSVI-50 and pCMVLacZ (Strategene) with 293
TransIT (Mirus) transfection reagent. Cells were passed at 48 h posttransfection
to hygromycin (250 μg/ml) and G418 (1.5 mg/ml) and further incubated for 1
to 2 weeks. Dual-drug-resistant colonies were picked and tested for isopropyl-
thiogalactopyranoside (IPTG)-induced expression of K-Rta with anti-Flag anti-
body.

Detection of supernatant virus. 293 cells plated onto 12-well tissue culture
dishes were infected with supernatant containing BAC36 or BAC36Δ50 virus
plus Polybrene (5 μg/ml). Supernatants were obtained from BAC36-
infected BCBL-1 cells treated with TPA or from the inducible cell line
293-LAC50 transfected with BAC constructs induced with IPTG. Supernatants
were centrifuged three times at 5,000 × g for 15 min to remove floating cells.
Cloned supernatants were then subjected to one freeze-thaw cycle and incu-
bated with fresh 293 cells. Green fluorescent protein (GFP) expression was used
to monitor infection.

RNA purification. 293 cells containing BAC36 or BAC36Δ50 were induced
with 10% of TPA per ml and harvested at various times postinduction. For the
293-LAC50 cell line, cells were transfected with BAC36 or BAC36Δ50 and total
RNA was harvested at various times post-IPTG treatment. Total RNA was
isolated with the Absolutely RNA reverse transcription-PCR miniprep kit (Strat-
agene, catalog number 400800) according to the instructions of the manufac-
turer. Residual DNA contamination was eliminated with Turbo DNase (Ambion, catalog number 1907). RNA quality was assessed by separation of RNA through a 1% formaldehyde denaturing agarose gel. Only samples with
260 nm/280 nm absorbance ratios of greater than 1.9 were used for subsequent
experiments.

Quantitative real-time PCR analysis. cDNA (20 μl) for real-time PCR was
generated from 2 μg of total RNA with the SuperScript First-Strand Synthesis
System (Invitrogen, catalog number 11904-018), priming with 25 ng of random
hexamer according to the manufacturer's instructions. cDNA was amplified in
sequences for the real-time TaqMan PCR system were chosen and synthesized
with Applied Biosystems's Assay-by-Design program (Applied Biosystems,
3431348) for ORF57, K8, K8.1, ORF40/41, and LANA genes, respectively (Table
1). The two unlabeled PCR primers and the FAM (6-carboxyfluorescein) dye-
labelled TaqMan MGB probe for each sequence were formulated into a single
tube, ready-to-use mixture at a 20X concentration. The real-time PCR
samples were performed with the TaqMan Universal PCR Master Mix (Applied Biosystems, catalog number 4304435), which consists of 10 mM Tris–HCl (pH 8.3), 30 mM
KCl, 5 mM MgCl2, 300 mM each dATP, dCTP, and dGTP, 600 mM dUTP, 0.625
U of AmpliTaq Gold DNA polymerase, was activated at 95°C for 10 min, followed by 40 cycles at 95°C for
15 s and at 60°C for 1 min. All reactions were carried out six times with a 7700
ABI Prism sequence detector (Applied Biosystems).

RNA isolated from the BCBL-1 cells was used to generate a standard curve for
each gene examined. The standard curve was used to calculate the relative
amount of specific cDNA present in a sample. Data from each sample was
normalized to human cyclophilin (Applied Biosystem, part 4326316E) levels for
the equal amount of cDNA input in each real-time PCR. As an additional
control, RNA from each sample without the reverse transcriptase step was
analyzed by real-time PCR to ensure that samples were free of external DNA.
Each experiment was performed 12 times, and error bars are the standard

Downloaded by guest from http://jvi.asm.org/ on November 11, 2017
TABLE 1. Primers and probes used for real-time PCR

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer and probe</th>
<th>Sequence (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORF59</td>
<td>Forward</td>
<td>TGGAAAGCCGTTGGAAGGA</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GTGAAATTGAGAAGTGGTTG</td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>CCACGGCTTCGCTCTCT</td>
</tr>
<tr>
<td>ORF57</td>
<td>Forward</td>
<td>CATTCCTAGAGGACTCTGT</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>TTGCTCGTCTCCGAGT</td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>TCTGAGTTTGAAGAACAT</td>
</tr>
<tr>
<td>ORF40-41</td>
<td>Forward</td>
<td>GAGAATACAAAGATCCCGGAAG</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GTTTACTCTGAGGG</td>
</tr>
<tr>
<td>K8</td>
<td>Forward</td>
<td>CAAGAGCGACTACATAAGAAA</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GATCATCTACTTCGGCTTAAC</td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>AGGACCGTTATGCAC</td>
</tr>
<tr>
<td>K8.1</td>
<td>Forward</td>
<td>AACATCCAGGACCAC</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>CGTCCTCGCAACACCTTTTA</td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>GGGAGGAAAGCTGGTTACG</td>
</tr>
<tr>
<td>LANA</td>
<td>Forward</td>
<td>CTTCCACGCGCAGCCTCT</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GGACCGCTTCTCTCTCT</td>
</tr>
</tbody>
</table>
tant virus upon treatment with TPA, an inducer of the viral lytic cycle. BAC36 and BAC36Δ50 were transfected into 293 cells, and cell lines were generated with hygromycin selection. Cell lines were treated with TPA, and supernatants were collected and used to inoculate fresh 293 cells. The wild-type (BAC36) virus-containing cell line was capable of producing infectious virus, as demonstrated by the appearance of green cells upon inoculation of fresh 293 cells (Fig. 2A). The cell line harboring BAC36Δ50 failed to produce green cells upon inoculation of fresh 293 cells with supernatants from BAC36Δ50-containing cells treated with TPA (Fig. 2B). However, when BAC36Δ50 was transfected into the inducible K-Rta cell line 293-LAC50, which was subsequently treated with IPTG to induce the expression of K-Rta, infectious virus was produced, as demonstrated by the appearance of green cells on freshly inoculated 293 cells (Fig. 2C). This indicated that the ORF50 mutant virus was capable of producing infectious virus when K-Rta was supplied in trans and that the mutation within the HHV8 BAC genome affected only the ORF50 locus.

Since the level of virus produced from TPA induction of 293 cells was very low, we examined K8 mRNA levels from 293-LAC50 cells transfected with BAC36 and BAC36Δ50. This was done to show that the expression of ORF50 could complement the mutation in BAC36Δ50. When cells were treated with IPTG, we observed a similar level of K8 mRNA accumulation between BAC36- and BAC36Δ50-containing cells (Fig. 2D). This demonstrated that the defect in BAC36Δ50 could be fully complemented, with respect to gene expression, by supplying ORF50 in trans.

We next examined the ability of BAC36Δ50 to accumulate viral DNA when induced with TPA. Since transient expression of K-Rta has been shown to activate viral gene expression, we sought to evaluate the level of viral DNA accumulation in the absence of K-Rta. We anticipated that the lack of K-Rta expression would result in failure of the virus to enter the lytic phase of DNA replication.

293 cells harboring either BAC36Δ50 or BAC36 latent viral DNA were treated with TPA or transfected with a K-Rta expression plasmid, pCMV-RTA 5′-Flag. Total cellular DNA was harvested at various days post-TPA treatment and transfection and viral DNA accumulation was evaluated by real-time PCR with primers and probes specific for the ORF59 gene locus (Table 1). Cells harboring BAC36Δ50 DNA failed to accumulate viral DNA in the presence of TPA for up to 7 days postinduction, whereas BAC36-transfected cells showed a significant increase in viral DNA accumulation (Fig. 3A). The transfection of a K-Rta expression plasmid, pCMV RTA 5′-Flag, had a similar effect to that of TPA treatment on BAC36

![Image](http://jvi.asm.org/)

**FIG. 2.** Complementation of BAC36Δ50 virus production by expression of K-Rta. For complementation, BAC-containing 293 cell lines were treated with TPA or 293-LAC50 cells were transfected with BAC36Δ50 and induced to express K-Rta by treatment with IPTG. Supernatants from each treatment were harvested 4 days postinduction and used to inoculate fresh 293 cells. (A) Cells were inoculated with supernatant from BAC36-containing 293 cells treated with TPA. (B) Cells were inoculated with supernatant from BAC36Δ50-containing 293 cells treated with TPA. (C) Cells were inoculated with supernatant from BAC36Δ50-transfected 293-Lac50 cells treated with IPTG. (D) IPTG induction of ORF50 complements the defect in BAC36Δ50. 293-LAC50 cells were transfected with BAC36 or BAC36Δ50 and treated with IPTG. Real-time PCR was performed, and the mRNA accumulation for K8 was determined.
treatment normally activates the expression of K-Rta resulting in the expression of viral early and late genes. One goal of the examination of viral early and late gene expression is to determine if these mRNA levels are affected by the absence of K-Rta expression in cell containing BAC36Δ50 DNA. We chose to evaluate the level of gene expression, with real-time PCR, from two early or delayed-early ORFs, K8 (K-bZIP) and ORF40/41, and the late gene K8.1. For these evaluations, the probes and primers used spanned the known spliced regions for these three transcripts (Table 1).

ORF40/41 is one of the components of the putative helicase-primase complex. This gene is normally expressed under conditions associated with lytic gene expression and participates in the enzymatic synthesis of HHV8 DNA (1, 2, 34). K-bZIP is the proposed origin binding protein and is also, along with ORF40/41, required for oriLyt-dependent DNA replication (1). Although the exact role of K-bZIP in DNA replication is unknown, it has been shown to be upregulated by K-Rta (4). K8.1 encodes a viral structural protein that displays true late-gene kinetics (17, 20, 28).

We compared mRNA levels from BAC36Δ50-containing cells treated with TPA to those obtained from cells containing the wild-type BAC36 when treated with TPA. mRNA accumulation is reported as the increase in accumulation over mRNA levels from the untreated BAC36-containing cell lines. K8 (K-bZIP) mRNA accumulation was almost 90-fold lower in BAC36Δ50-containing cells treated with TPA at 72 h postinduction and was comparable to that in untreated cells (Fig. 4, K8 graph). As expected, an increase in K8 mRNA accumulation was observed from 24 to 72 h post-TPA treatment in BAC36 samples.

When BAC36Δ50-containing cells were treated with TPA, mRNA accumulation for the early transcript encoding ORF40/41 remained at levels similar to those observed from untreated cells (Fig. 4, ORF40/41 graph). No significant increase in ORF40/41 mRNA accumulation was observed at any time point tested (Fig. 4, ORF40/41 graph). The late gene transcript encoding the viral structural protein K8.1 was also unaffected in TPA-treated BAC36Δ50-containing cells and remained at mRNA accumulation levels similar to those observed from untreated samples (Fig. 4, graph K8.1). Although mRNA accumulation in TPA-treated BAC36Δ50-containing cells was only about fourfold higher than those observed from untreated cells at 72 h posttreatment, mRNA accumulation in BAC36Δ50-containing cells was almost undetectable (Fig. 4, K8.1 graph). These results indicated that early and late viral mRNA accumulation in BAC36Δ50-containing cells was defective and strongly suggested that the lack of K-Rta expression has a profound effect on mRNA induction for these genes.

As a control, we examined the mRNA levels for the latency-associated transcript LANA. Since BAC36- and BAC36Δ50-containing cells should accumulate equal amounts of LANA RNA, this should serve as a good internal control for overall gene expression patterns between the two cell lines. As can be seen in Fig. 4, the levels of LANA mRNA accumulation were similar between the cell lines throughout TPA treatment.

ORF57 gene expression is upregulated in the absence of K-Rta expression. Since we demonstrated that the absence of K-Rta expression had a deleterious effect on the mRNA levels of two early genes, we next wanted to evaluate the mRNA accumulation (Fig. 3B). In addition, the introduction of the K-Rta expression plasmid into cells harboring BAC36Δ50 resulted in an increase in mutant BAC viral DNA similar to that observed from BAC36-containing cells (Fig. 3B). These results indicated that BAC36Δ50 was defective for viral DNA synthesis and this defect was abolished upon transfection of a K-Rta expression vector, and total cellular DNA was harvested 48 h posttransfection, and real-time PCR was performed to determine viral DNA accumulation. Error bars are the standard deviations from 4 experiments.

Early and late viral gene expression is defective in BAC36Δ50-containing cells. Since we were unable to detect an increase in accumulation of viral DNA or production of supernatant virus from BAC36Δ50-containing cells induced with TPA, we wanted to survey key mRNAs corresponding to viral transcripts from each kinetic class with real-time PCR. We evaluated various viral mRNA levels in cells containing either BAC36Δ50 or BAC36 DNA upon treatment with TPA. TPA...
levels of an immediate-early gene. We selected ORF57 since it is the homolog of Epstein-Barr virus Mta, an immediate-early gene involved in reactivation and DNA replication. However, transient HHV8 assays revealed that the promoter for ORF57 was transactivated by K-Rta, and Northern analysis revealed that ORF57 mRNA was detected at about 4 h post-TPA treatment a short time after ORF50 expression (16). Neither of these observations gives a clear indication that K-Rta is required for the expression of ORF57 in the context of the viral genome.

Consequently, we examined relative mRNA accumulation of ORF57 in BAC36Δ50-containing cells versus accumulation in BAC36-containing cells. Cells were treated with TPA, and RNA was harvested at various times posttreatment, and real-time PCR was performed with a probe specific for ORF57 (spanning an intron, see Table 1). Interestingly, mRNA accumulation of ORF57 was approximately fivefold higher at 72 h post-TPA treatment in BAC36Δ50-containing cells compared to TPA-treated BAC36-containing cells (Fig. 4, ORF57 graph). ORF57 mRNA accumulation was over 20-fold higher than that observed in uninduced cells (Fig. 4, ORF57 graph). This result suggests that, in contrast to observations from transient promoter assays where ORF50 upregulated ORF57 expression, the lack of K-Rta in the virus genome resulted in an increase, or dysregulation, of ORF57 expression, resulting in higher mRNA accumulations than in BAC36-containing cells under similar conditions.

**Evaluation of LANA, ORF59, and K8.1 protein expression in BAC36- and BAC36Δ50-containing 293 cells.** Since we observed aberrant transcript levels for selected early and late HHV8 genes, we next sought to evaluate the protein expression of representative latent, early, and late genes by immunofluorescence staining of TPA-induced BAC36- and BAC36Δ50-containing cells. 293 cells containing either BAC36 or BAC36Δ50 were treated with TPA and reacted with antibodies specific for LANA, ORF59, or K8.1. Both BAC36- and BAC36Δ50-containing cells expressed the latency-specific protein LANA, indicating that the mutant BAC was capable of establishing a latent state within 293 cells (Fig. 5, LANA panel). However, when the cells were evaluated for the expression of ORF59, which encodes the polymerase accessory protein, only wild-type-BAC-containing cells reacted positively with the antibody specific for this protein (Fig. 5, ORF59 panel). In addition, when cells were reacted with the antibody specific for K8.1, no positive BAC36Δ50-containing cells were observed (Fig. 5, K8.1 panel). These results confirmed that the expression of K8.1 was aberrant in BAC36Δ50-containing cells and also established that the replication protein ORF59 was not expressed in TPA-treated mutant BAC-containing cells. However, both wild-type and mutant BAC viral DNAs were
capable of establishing a latent environment within 293 cells, as was evident by the efficient expression of LANA.

DISCUSSION

HHV8 has many features in common with the closely related gammaherpesvirus Epstein-Barr virus. However, some noted differences include the apparent mechanism involved in the initiation of lytic reactivation and DNA replication. For HHV8, K-Rta, the gene product of ORF50, the homolog of Epstein-Barr virus Rta, is sufficient for lytic reactivation when introduced into latently infected cells (6, 16). K-Rta has strong transactivation properties and evidently activates HHV8 early and late genes upon transfection into latently infected cells (4, 6, 15, 16, 21, 24, 29). For Epstein-Barr virus, it is Zta, the homolog of HHV8 K8 (K-bZIP), that drives the lytic cycle. In HHV8, the gene product of K8 has no transactivation function and appears to be regulated by ORF50 (K-Rta). Also, K-Rta and K8 (K-bZIP) are required for origin-dependent DNA replication (1). K-Rta appears to activate gene expression by directly interacting with a K-Rta-responsive element within oriLyt (1). This scenario is again in contrast to Epstein-Barr virus, where it is Zta that apparently performs essential transactivation and DNA replication functions with Epstein-Barr virus oriLyt (22).

ORF50 is the product of a spliced transcript that can be detected as early as 1 h post-TPA treatment (16). The ORF50 gene product, K-Rta, is a highly phosphorylated protein that was initially shown to be necessary for lytic reactivation. In addition, K-Rta upregulates its own expression through a mechanism involving the binding of the transcription factor Oct-I to sequences within the promoter region (21). K-Rta appears to activate gene expression by directly interacting with elements within promoters for several early genes and the immediate-early gene encoding ORF57 (15). Although in some cases these activation elements share some sequence homology, there appear to be many distinct K-Rta activation elements controlling the expression of various viral proteins (4, 15, 24). In addition to direct binding of K-Rta to promoter elements, cellular factors also contribute to the transactivation
of viral gene expression (30). However, it is the repression of K-Rta expression that maintains the latent state of the virus. This control of K-Rta expression may be due to histone modification and chromatin remodeling, resulting in the hindrance of transcriptional activation of the ORF50 gene (14).

We have now demonstrated that the lack of K-Rta expression in the context of the viral genome results in a null phenotype with respect to early gene expression, virus production, and DNA synthesis. No increase in the accumulation of viral BAC36Δ50 DNA was observed in the presence of TPA, indicating that the normal process of lytic cycle induction was defective when K-Rta expression was abolished. For real-time PCR analysis of viral mRNAs, we chose to evaluate only spliced mRNAs (except for LANa). All primers and probes were designed so that they spanned an intron. This eliminated the possibility that the observed signal was from the viral genome. Although in most cases the accumulation of viral mRNAs from TPA-treated BAC36-containing cells was modest, the mutant BAC consistently showed much lower accumulation levels and was similar to those obtained from untreated cells.

mRNA accumulation for early and late gene expression from BAC36Δ50-containing cells treated with TPA was consistent with a viral phenotype with a defect in transcriptional activation. Although transient transfection experiments show that K-bZIP and ORF57 are upregulated by K-Rta, there are no data concerning the activation of ORF40/41 by K-Rta. We assume, however, that ORF40/41 mRNA production is also influenced by K-Rtas and the onset of viral DNA synthesis. It is for this reason that we believe that the ORF40/41 mRNA accumulation pattern is similar to that of K8 in TPA-induced mutant virus-containing cells. Indeed, our data support the hypothesis that ORF40/41, and probably all other replication genes, is dependent on the expression of K-Rta.

Our results also suggest that there is an apparent dysregulation of the expression of another viral transactivator, ORF57, in the absence of K-Rta expression. This is in contrast to findings from transient assays where K-Rta transactivated ORF57 expression (15, 24, 29). ORF57 protein was found to act synergistically with ORF50 (K-Rta) to upregulate the expression of some HHV8 gene-specific promoters and to have an effect on the accumulation of several viral mRNAs (9). Recently, it was demonstrated that ORF57 interacts with K-Rta and this protein complex upregulated K-Rta expression in transient assays (18). The ORF57 gene product is the predicted homolog of Epstein-Barr virus BMFL1 (Mta) (5, 23). Mta is one of three major transacting factors encoded by Epstein-Barr virus and was shown to bind to specific RNAs and shuttle them between the nucleus and cytoplasm (23).

For HHV8, ORF57 is characterized as a lytic gene, and expression can be seen between 2 and 4 h post-TPA treatment in BCLB-1 cells (16). ORF57 itself is the product of a spliced transcript, and the protein product is localized to the cell nucleus (9). One reason for the increase in mRNA accumulation of ORF57 in cells containing BAC36Δ50 could be that K-Rta may serve to downregulate the expression of ORF57 at very early times after lytic cycle induction. When this regulation is removed, as in the case of a mutant virus unable to express K-Rta, then the levels of ORF57 mRNA may increase. Another possibility is that K-Rta may destabilize ORF57 mRNA in lytically infected cells and thereby regulate the effects of ORF57 posttranscriptionally.

We used an inducible cell line to complement viral growth and DNA synthesis of BAC36Δ50. We developed this inducible K-Rta system because of the apparent toxicity of constitutive expression of K-Rta in trans. We were also able to induce lytic replication from wild-type BAC (BAC36) upon transfection and subsequent IPTG induction of the K-Rta-containing 293 cell line. As observed in other studies, we also had a low level of production of infectious virus from BAC36Δ50 cells upon induction with TPA (17). Nevertheless, the numbers of green cells observed upon inoculation of fresh 293 cells with supernatants from either TPA-treated BAC36 or complemented BAC36Δ50-containing cells were similar. This indicated that expression of K-Rta in trans was sufficient to supply all the functions necessary for progression to the lytic cycle.

ACKNOWLEDGMENTS

This work was supported by PHS grant CA085164. We thank S. Gao for the BAC36 construct and Ren Sun for the K-Rta expression construct.

REFERENCES

32. Wang, S. E., F. Y. Wu, Y. Yu, and G. S. Hayward. 2003. CCAAT/enhancer-binding Protein-alpha is induced during the early stages of Kaposi’s Sarcoma-associated herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and PAN promoters. J. Virol. 77:9590–9612.